Patient Input Needed For Review Of New Migraine Medicine By Nov 30
 |
| Photo copyright The Headache & Migraine Policy Forum |
The Institute for Clinical and Economic Review (ICER) is assessing the first CGRP submitted for FDA approval. Insurance companies will use ICER’s selesai report (as well as other information) when determining if they will cover this medicine (and other medicines in this class that are expected to follow), what tier the medicine will be in on the plan’s formulary, and what types of prior authorization or step therapy will be required.
It is critically important that ICER understands the migraine patient experience. You can help.
Call to Action: Patient input must be received by November 30, 2017. You can access the online submission form here.
This is your story to tell and a chance to be heard and advocate. Join us in showing that we are a strong, united front to be taken seriously.
Patient Guide: For a preview of the eight questions ICER asks patients and guidance on key points to include in your response, read HMPF's Patient Guide.
Have Questions? A teleconference to educate patients and to answer your questions about the ICER Open Input period will be held on Tuesday, November 28 at 3:00pm ET. Click here to register for this free teleconference.
